Saturday 17 October 2026
Export HRMY’s income statement to Excel — free account
Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
38.20
0.07
−0.18%
Follow HRMY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.63 | 11.12 | 13.61 | 8.53 |
+8 more quarters Free account |
P/S ratio |
2.20 | 1.80 | 2.48 | 1.92 | |
P/FCF ratio |
6.70 | 5.37 | 6.99 | 6.17 | |
P/Operating CF |
22.82 | 58.34 | 17.05 | 14.59 | |
P/B ratio |
2.11 | 1.78 | 2.47 | 1.90 | |
Price to Tangible BV |
2.29 | 1.96 | 2.76 | 2.14 | |
EV/Sales |
1.66 | 1.27 | 1.77 | 1.31 | |
EV/EBITDA |
6.25 | 5.31 | 6.61 | 4.36 | |
EV/Operating CF |
4.49 | 3.33 | 4.42 | 3.64 | |
EV/FCF |
5.07 | 3.77 | 5.00 | 4.21 | |
Quick Ratio |
3.33 | 3.45 | 3.46 | 3.46 | |
Current Ratio |
3.48 | 3.58 | 3.60 | 3.75 | |
Net Debt/EBITDA |
(5.41) | (11.16) | (13.34) | (7.07) | |
Debt/Assets |
11.21% | 12.49% | 12.87% | 13.95% | |
Debt/Equity |
0.15 | 0.17 | 0.19 | 0.20 | |
Asset Turnover |
0.77 | 0.77 | 0.76 | 0.77 | |
Operating CF/Net income |
1.23 | 0.85 | 5.61 | 2.14 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | (0.01) | |
Interest Coverage |
29.09 | 11.53 | 10.87 | 18.09 | |
Research and Development Expense of Revenue |
17.83% | 32.21% | 20.48% | 22.95% | |
Selling, General and Administrative Expense of Revenue |
23.79% | 29.81% | 35.58% | 24.79% | |
Intangible Assets out of Total Assets |
0.06 | 0.07 | 0.07 | 0.08 | |
Share Based Compensation of Revenue |
3.57% | 4.93% | 4.09% | 4.58% | |
Graham Net Nets |
0.21 | 0.26 | 0.24 | 0.29 | |
Graham Number |
34.85 | 29.88 | 30.60 | 32.47 | |
Earnings Yield |
8.60% | 9.00% | 7.35% | 11.72% | |
Free Cash Flow Yield |
14.92% | 18.63% | 14.31% | 16.20% | |
Revenue per Share |
4.51 | 3.73 | 4.24 | 4.16 | |
Operating CF per Share |
1.60 | 0.48 | 2.19 | 1.89 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
1.60 | 0.48 | 2.19 | 1.89 | |
Cash per Share |
11.53 | 11.08 | 13.49 | 11.69 | |
Shareholders Equity per Share |
17.25 | 15.74 | 15.14 | 14.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.25 | 15.74 | 15.14 | 14.51 | |
Free Cash Flow |
92.43 | 27.76 | 126.04 | 108.66 | |
Working Capital |
580.26 | 561.48 | 654.88 | 615.40 | |
Capital Expenditures |
— | — | (0.11) | (0.07) | |
Net Current Asset Value |
440.49 | 417.34 | 505.60 | 465.71 | |
EV/EBIT |
6.92 | 6.00 | 7.39 | 4.80 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
9.15 | 8.55 | 10.32 | 7.03 | |
| Other line items | |||||
Average Receivables |
101.99 | 107.10 | 89.91 | 91.08 | |
Average Payables |
24.99 | 23.03 | 15.72 | 18.44 | |
Average Inventory |
6.23 | 5.83 | 6.28 | 6.90 | |
Average Assets |
1,240.55 | 1,163.68 | 1,135.42 | 1,068.18 | |
Average Common Equity |
886.16 | 815.44 | 764.69 | 715.96 |
Columns are period end dates